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T.Barber@warwick.ac.ukSummaryA 19-year-old woman was diagnosed with osteogenesis imperfecta (OI). She had sustained numerous low-trauma fractures
throughout her childhood, including a recent pelvic fracture (superior and inferior ramus) following a low-impact fall. Shehad
the classical blue sclerae, and dual energy X-ray absorptiometry (DEXA) bone scanning confirmed lowbonemass for her age in
the lumbar spine (Z-score wasK2.6). However, despite these classical clinical features, the diagnosis of OI had not been
entertained throughout thewhole of her childhood. Sequencing of her genomic DNA revealed that shewas heterozygous for
the c.3880_3883dupmutation in exon 50 of the COL1A1 gene. Thismutation is predicted to result in a frameshift at p.Thr1295,
and truncating stop codon3aminoacidsdownstream. Toour knowledge, thismutationhasnotpreviously been reported inOI.Learning points:
† OI is a rare but important genetic metabolic bone and connective tissue disorder that manifests a diverse clinical
phenotype that includes recurrent low-impact fractures.
† Most mutations that underlie OI occur within exon 50 of the COL1A1 gene (coding for protein constituents of type 1
pro-collagen).
† The diagnosis of OI is easily missed in its mild form. Early diagnosis is important, and there is a need for improved
awareness of OI among health care professionals.
† OI is a diagnosis of exclusion, although the key diagnostic criterion is through genetic testing for mutations within
the COL1A1 gene.
† Effective management of OI should be instituted through a multidisciplinary team approach that includes a bone
specialist (usually an endocrinologist or rheumatologist), a geneticist, an audiometrist and a genetic counsellor.
Physiotherapy and orthopaedic surgery may also be required.Background
Osteogenesis imperfecta (OI) is a heterogeneous connec-
tive tissue disorder that manifests clinically as extreme
bone fragility, brittleness and growth disorder (1).Although the commonest bone genetic disorder, OI is
rare with a prevalence of 1/10 000 births (2). OI manifests a
wide range of phenotypic characteristics and clinical
severities with at least eight sub-types having beenhttp://www.edmcasereports.com
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severity of OI can make its effective diagnosis a clinical
challenge. Early and effective management of OI through
a multidisciplinary approach is important as delayed
diagnosis of this condition can result in significant
morbidity (avoidable through timely intervention) (1).
In this case report, we present the case of a young woman
with a new diagnosis of OI following multiple low-trauma
fractures throughout her childhood, in whom we
have identified a novel mutation in exon 50 of the
COL1A1 gene.Figure 1
X-ray of pelvis demonstrating fractures of the left superior and inferior
pubic rami.Case presentation
The case is that of a 19-year-old female student who was
referred to the Endocrine Clinic at the Warwickshire
Institute for the Study of Diabetes, Endocrinology and
Metabolism (WISDEM), University Hospitals Coventry
and Warwickshire, following a low-impact fall that
resulted in superior and inferior fractures of her pelvic
rami. This injury was sustained when she tripped and fell
onto the pavement from a standing position. Her medical
history revealed numerous fractures, including tibia,
clavicle and metacarpals, all resulting from low-impact
falls. These fractures were sustained throughout her
childhood, with the first one occurring at the age of
5 years. Other relevant history included current treatment
for an eating disorder (anorexia nervosa). There was no
family history of note, and in particular no family history
of low-trauma fractures in her parents, brother or other
family members. Her only medication was the combined
oral contraceptive pill (Microgynon), which she had been
taking for 3 years for contraceptive purposes. Prior to this,
she had been oligo-amenorrhoeic (resulting from her
being underweight). She was a smoker (10–15 cigarettes/
day) and only rarely drank alcohol. On systemic enquiry,
she had a history of recurrent chest infections and poor
hearing. She was born at term (normal vaginal delivery)
and had normal early development, having achieved
early-life developmental milestones (including physical,
emotional, language, social and cognitive development)
at appropriate ages.
On examination, she was underweight with a BMI of
17.9 kg/m2. Her weight was 52 kg and height was
170.3 cm. She had blue discolouration to her sclerae
bilaterally, but her dentition was good. Other than
bilateral clinodactyly, her musculoskeletal examination
revealed no deformity, tenderness or weakness, and there
was no chest wall deformity. It was, however, noted that
she had some increased laxity to the joints in her upperhttp://www.edmcasereports.comlimbs (including elbow, meta-carpal and phalangeal
joints in both arms and hands). While Rinne’s test was
positive on both sides, Weber’s test localised to the right
side, suggesting either partial ipsilateral conductive
hearing defect or (more likely) contralateral sensorineural
hearing loss.Investigation
Biochemically, her full blood count and renal and liver
functions were normal, and her serum calcium, mag-
nesium, phosphate, alkaline phosphatase and 25-hydro-
xycholecalciferol levels were within their normal ranges.
Baseline P1NP was in the lower part of the normal range
(due to the reduced production of type 1 collagen in OI
type 1). Her pelvic X-rays confirmed fractures to the
superior and inferior rami (Fig. 1). The dual energy X-ray
absorptiometry (DEXA) bone scan revealed low bone mass
for her age within her lumbar vertebrae (Z-scoreK2.6 (low
bone mass for age being defined as a Z-score!K1.0)) but
normal bone mass for her age in her hips (Z-score K0.8
(normal bone mass for age being defined as a Z-score
OK1.0)). Sequencing of her genomic DNA revealed that
she is heterozygous for the c.3880_3883dup mutation in
exon 50 of the COL1A1 gene. This mutation is predicted to
result in a frameshift at p.Thr1295 and truncating stop
codon 3 amino acids downstream.Treatment
Following confirmation of a diagnosis of OI type 1, the
initial step in her management was to advise her on
lifestyle modifications, particularly in relation to her2
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she was advised to avoid any lifting of heavy loads.
Furthermore, with the patient’s consent, a letter was
written to her employer outlining her new diagnosis and
the importance of avoiding any heavy lifting or other
physical activities that may put her at risk of further
fracture. Prior to initiation onto bisphosphonate therapy,
she was fully informed and counselled regarding the
potential teratogenic effects of these agents and to avoid
pregnancy while on this drug. Following her consent,
weekly alendronate therapy was commenced on her with
calcium and vitamin D supplementation. Her response to
bisphosphonate therapy will be monitored at future
appointments with repeat DEXA bone scans. She will
continue with the combined oral contraceptive pill. She
has no plans for pregnancies but this will be discussed at
future appointments and a decision regarding future
bisphosphonate therapy made accordingly. She was
referred to a geneticist and genetic counselling for further
input in relation to the implications of her newly
identified novel mutation for her, any future offspring
and her relatives. She was advised regarding pregnancy
and the need for close multidisciplinary follow-up during
any future pregnancy and the possible complications for
both her and the foetus during any future pregnancy. In
view of her hearing impairment, she was referred to
audiology for formal assessment of her hearing and further
follow-up.Outcome and follow-up
The patient made excellent progress and has follow-up in a
multidisciplinary outpatient setting. She has had no
further fractures since implementation of her lifestyle
advice. She has had genetic counselling and has excellent
understanding of her condition and the implications for
any future pregnancy. She tolerates bisphosphonate
therapy and has regular audiometry assessments. Manage-
ment is currently successful through lifestyle, conservative
and pharmacological-based therapies. We plan to con-
tinue the alendronate therapy for a period of 3 years
initially to assess for any beneficial effects on bone mineral
density. Owing to the incorporation of bisphosphonates
into the bone matrix and subsequent release back into the
serum, there is a theoretical teratogenic risk of these
agents even following their discontinuation. Therefore,
avoidance of pregnancy and use of a reliable form of
contraception is important during therapy with a bis-
phosphonate and for at least 1 year following its
discontinuation.http://www.edmcasereports.comDiscussion
OI is a heterogeneous connective tissue disorder that
results from defective production of type 1 collagen.
Although OI is the commonest genetic bone disorder, its
overall prevalence is rare and estimated to be 1 in 10 000–
20 000 births (2). Characterised by bone fragility, OI
manifests clinically as increased susceptibility to bone
fractures (3) that often result from low-impact trauma (4)
(as illustrated in this case). Although screening for OI
should be considered in patients sustaining unusual low-
impact fractures, it should also be noted that pelvic
fracture is very unusual even in patients with OI of this
age. It is noteworthy in this case that she had a co-existing
diagnosis of anorexia nervosa, which is a major risk factor
for low bone mass and fractures. This is relevant to her
presentation in late adolescence and is likely to have been
a contributory factor (augmenting the effects of OI) to her
history of recurrent low-trauma fractures.
The phenotype of OI is diverse and is influenced by
the genetic mutation responsible. This combined with the
rarity of OI presents a diagnostic challenge (5). The case
described here has the mildest form of OI type 1, which is
also the most commonly encountered subtype (1) (3) and
is associated with a propensity towards low-trauma
fractures (5) (6). A common manifestation of OI type 1
(also demonstrated in this case) is presenile sensorineural
hearing loss (5). There are in excess of 800 mutations
associated with OI including more than ten reported
mutations occurring within exon 50 of the COL1A1 gene
(7) (8) (9) (10). Patients with OI manifest heterozygous
mutations (presumably because homozygous variants die
in utero). The vast majority of patients with OI (90%) have
a point mutation in one of two genes: COL1A1 or COL1A2.
These genes code for protein constituents of type 1
pro-collagen (proa1 and proa2 chains respectively) (3).
OI type 1 results from mutations in COL1A1 that cause a
quantitative defect of type 1 collagen. Genome sequen-
cing in this case identified heterozygosity for the
c.3880_3883dup mutation in exon 50 of the COL1A1
gene. This mutation produces a frameshift at p.Thr1295
that results in a truncating stop codon 3 amino acids
downstream. Although there are several similar mutations
published in this region of COL1A1 (some of which
have similar phenotypes; Table 1 (7) (8) (9) (10)), to our
knowledge, the mutation in COL1A1 identified here has
not previously been reported in OI.
The challenge of diagnosing OI in clinical practice is
heightened when there is a lack of family history for the
condition or its characteristic features. While bilateral blue3
Table 1 Outline of some reported mutations in exon 50 of the COL1A1 gene associated with OI. Data are also shown for type of
mutation, affected protein, downstream effect and sub-type of OI reported. Details of the novel mutation discussed in this case
report are also included.
Exon
location
Reported
change in DNA
Initial effect of
the mutation
Effect on
downstream
protein Further effects
OI type (clinical/
phenotype) Reference
50 c.3829 G/C Substitution p.Asp1277His Asp1099His I, II (7)
Missense
50 c.3831 C/G Substitution p.Asp1277Glu – II (8)
Missense
50 c.3880_3883dup Duplication p.Thr1295 Truncating stop codon
3 amino acids
downstream
I Our case
Frameshift
50 c.3897 C/G Substitution p.Cys1299Trp Cys1121Trp I (9)
Missense
50 c.3910 C/T Substitution p.(Gln1304*) Gln1162Stop I (10)
Nonsense
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ential diagnosis of this clinical sign includes numerous
other conditions including Ehlers–Danlos syndrome and
Marfan’s syndrome. OI is a diagnosis of exclusion, and
there are no minimum diagnostic criteria. The key
diagnostic assessment for OI is genetic testing of blood
or saliva specimens for COL1A1 mutations (6) (dermal
fibroblast culture from skin biopsies (to identify
pro-collagen expression) can also be useful diagnostically
(2) (3)). Genotyping for suspected cases of OI is an
expensive investigation and should be considered care-
fully in each suspected case. Genetic testing is often
indicated when there is clinical suspicion of OI associated
with some atypical features. However, the presence of
clear clinical features of OI limits the utility of genotyping
and often renders this investigation unnecessary. Further-
more, the presence of clear clinical features of OI often
enables effective management to be implemented, and
clinical genetics advice is provided (including advice
about future offspring) solely based on phenotype.
Despite the classical clinical presentation of OI, and the
frequentassessmentsbynumeroushealthcareprofessionals
following recurrent low-impact fractures in this case, it is
interesting that a diagnosis ofOIwasnotentertainedearlier.
The rarity of OI and the apparent lack of awareness of this
condition among health care professionals may have been
contributory. Improving awareness of OI, particularly
among ‘front-line’ NHS staff (including GPs and emergency
care doctors), should be a priority.
Management of OI should be through a multidisciplin-
ary approach that includes input from a specialist in bone
health (endocrinologist or rheumatologist), audiologist,http://www.edmcasereports.comgeneticist, genetic counsellor and occasionally physiothera-
pist and orthopaedic surgeon. The potential effects of any
future pregnancy on the mother and foetus need to be
considered carefully. The principals of effective manage-
ment of OI are to reduce the risk of fractures, minimise
skeletal deformity and maximise quality of life (2). Manage-
ment of OI type 1 typically comprises a combined
conservative and pharmacological approach: avoidance of
heavy lifting and impact sports; use of splints; physiother-
apy to address joint laxity; and vitamin D and calcium
supplements. Regular (multidisciplinary) outpatient follow-
up is required. With regard to bisphosphonate therapy in OI,
there is little evidence in the literature that these agents
actually improve fracture rates, although they have been
shown to improve bone mineral density. The optimal
duration of bisphosphonate therapy in OI is not clear, and
future studies are required to address this. The use of
bisphosphonate therapy in women of childbearing age
should be considered carefully. Each patient should be
counselled appropriately prior to the initiation of any
bisphosphonate therapy regarding the potential teratogenic
effects of these agents (both during their use and following
their discontinuation). Clearly, a reliable form of contra-
ceptive should be used while on these agents and for at least
a year following their discontinuation.
To conclude, we present the case of a young woman
with a long-standing history of low-impact fractures and
the characteristic bilateral blue sclerae of OI type 1.
Genetic testing revealed a heterozygous novel frameshift
mutation (c.3880_3883dup) in exon 50 of the gene
COL1A1 that results in a truncating stop codon.
This case illustrates the importance of early diagnosis4
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effective management plan through a multidisciplinary
approach in patients with OI. To our knowledge, this
is also the first report of the novel mutation,
c.3880_3883dup within exon 50 of the COL1A1 gene
presenting with the phenotype of OI type 1.Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.Funding
This research did not receive any specific grant from any funding agency in
the public, commercial or not-for-profit sector.Patient consent
Informed consent has been obtained from the patient for publication of
this (anonymised) submitted case report and accompanying images.Author contribution statement
All authors listed contributed substantially to the preparation of this
manuscript. The corresponding author (T M Barber) is the named physician
of the patient.References
1 Strevel EL, Papaioannou A, Adachi JD & McNamara M 2005 Case report:
osteogenesis imperfecta elusive cause of fractures. Canadian Family
Physician Me´decin de Famille Canadien 51 1655–1657.http://www.edmcasereports.com2 Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F,
Perlini S, Cavarzere P & Antoniazzi F 2010 Current and emerging
treatments for the management of osteogenesis imperfecta. Journal of
Therapeutics and Clinical Risk Management 6 367–381.
3 van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A,
Rohrbach M, Symoens S, Sistermans EA & Pals G 2012 EMQN best
practice guidelines for the laboratory diagnosis of osteogenesis
imperfecta. European Journal of Human Genetics 20 11–19.
(doi:10.1038/ejhg.2011.141)
4 Wekre LL, Eriksen EF & Falch JA 2011 Bone mass, bone markers and
prevalence of fractures in adults with osteogenesis imperfecta.
Archives of Osteoporosis 6 31–38. (doi:10.1007/s11657-011-
0054-z)
5 Sillence DO, Senn A & Danks DM 1979 Genetic heterogeneity in
osteogenesis imperfecta. Journal of Medical Genetics 16 101–116.
(doi:10.1136/jmg.16.2.101)
6 Cheung MS & Glorieux FH 2008 Osteogenesis imperfecta: update on
presentation and management. Reviews in Endocrine & Metabolic
Disorders 9 153–160. (doi:10.1007/s11154-008-9074-4)
7 Chessler SD, Wallis GA & Byers PH 1993 Mutations in the carboxyl-
terminal propeptide of the pro alpha 1(I) chain of type I collagen
result in defective chain association and produce lethal
osteogenesis imperfecta. Journal of Biological Chemistry 268
18218–18225.
8 Pyott SM, Pepin MG, Schwarze U, Yang K, Smith G & Byers PH 2011
Recurrence of perinatal lethal osteogenesis imperfecta in sibships:
parsing the risk between parental mosaicism for dominant mutations
and autosomal recessive inheritance. Genetics in Medicine 13 125–130.
(doi:10.1097/GIM.0b013e318202e0f6)
9 Pace JM, Kuslich CD, Willing MC & Byers PH 2001 Disruption of one
intra-chain disulphide bond in the carboxyl-terminal propeptide of the
proalpha1(I) chain of type I procollagen permits slow assembly and
secretion of overmodified, but stable procollagen trimers and results in
mild osteogenesis imperfecta. Journal of Medical Genetics 38 443–449.
(doi:10.1136/jmg.38.7.443)
10 Swinnen FK, De Leenheer EM, Coucke PJ, Cremers CW & Dhooge IJ
2009 Audiometric, surgical, and genetic findings in 15 ears of patients
with osteogenesis imperfecta. Laryngoscope 119 1171–1179.
(doi:10.1002/lary.20155)Received in final form 21 May 2013
Accepted 30 May 20135
